CStone Pharmaceuticals-B (02616) has entered into a clinical development collaboration with Kimia Therapeutics to jointly advance an innovative drug candidate targeting a key repair pathway in solid tumors.

CStone Pharmaceuticals-B (02616) announced that the company has entered into a collaboration with Kimia Therapeutics, Inc. ("Kimia"), a biopharmaceutical company focused on the research and development of innovative oncology and immunology drugs. The two parties will jointly advance the clinical development of a solid tumor drug candidate with first-in-class potential that targets the DNA damage response (DDR) pathway critical to solid tumor survival. CStone Pharmaceuticals will lead the clinical development of the drug candidate in mainland China and Australia.